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The increasing recognition of cyclic vomiting syndrome (CVS) in adults prompted the 
developmentoftheseevidence-basedguidelinesonthemanagementofCVSinadults,
whichwassponsoredbytheAmericanNeurogastroenterologyandMotilitySociety
(ANMS) and the Cyclic Vomiting Syndrome Association (CVSA). GRADE (Grading
of Recommendations, Assessment, Development, and Evaluation) frameworkwas
usedandaprofessional librarianperformedtheliteraturesearch.Theexpertcom-
mitteeincludedthePresidentoftheCVSAwhobroughtapatientperspectiveinto
the deliberations. The committeemakes recommendations for the prophylaxis of
CVS, treatment of acute attacks, diagnosis, and overallmanagement ofCVS. The
committeestronglyrecommendsthatadultswithmoderate-to-severeCVSreceive
a tricyclic antidepressant (TCA), such as amitriptyline, as a first-line prophylactic





such as ondansetron, and/or triptans, such as sumatriptan or aprepitant to abort
symptoms. Emergency department treatment is best achievedwith the use of an
individualizedtreatmentprotocolandsharedwiththecareteam(exampleprovided).
The committee recommended screening and treatment for comorbid conditions such 
asanxiety,depression,migraineheadache,autonomicdysfunction,sleepdisorders,
and substance use with referral to appropriate allied health services as indicated. 
Techniqueslikemeditation,relaxation,andbiofeedbackmaybeofferedascomple-
mentarytherapytoimproveoverallwell-beingandpatientcareoutcomes.
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1  | INTRODUC TION
Cyclic vomiting syndrome (CVS) is a chronic functional gastrointes-
tinal disorder that is being increasingly recognized in adults.1,2 It is 
characterized by episodic nausea and vomiting and is associated 
with significant morbidity. Approximately one-third of adult pa-





IV symptom-based criteria established a uniform, symptom-based
frameworkthat isuseful inclinicalpractice.Whileotherdisorders
of nausea and vomiting such as gastroparesis may be confused with 
CVS, these disorders lack the stereotypical and sudden onset of
symptoms,featuresthatappeartobefairlyuniquetoCVS.Withfur-
therresearch,theclinicalfeaturesofCVSwillbecomebetterdeline-
ated,andthis information is likely to influencefuture iterationsof
symptom-basedCVSdiagnosticcriteria.Forexample,manypatients
withCVSexperienceabdominalpainduringanacuteattack,butthis
feature is not currently incorporated in the Rome IV CVS criteria and 
should be considered in future revisions.
This article represents an official statement of the American
NeurogastroenterologyandMotilitySociety (ANMS)andtheCyclic
VomitingSyndromeAssociation (CVSA)on thediagnosis andman-
agement of CVS in adults. The target audience for this guideline in-
cludesgastroenterologists,emergencymedicinephysicians,primary
careproviders,otherclinicians,patients,andpolicymakers.Thecom-
mittee developed and graded the recommendations and assessed 
thecertaintyintheevidenceusingtheGradingofRecommendations,
Assessment, Development, and Evaluation (GRADE) framework.6 
The committee members, whowere selected jointly by the CVSA
and a councilmember of theANMS clinical guidelines committee,
included primarily gastroenterologists with clinical and research 
expertise,providers fromotherdisciplines, suchaspsychologyand
neurology, methodologists with experience in evidence appraisal
andguidelinedevelopment,andonepatientrepresentative,whowas
alsoPresidentoftheCVSA.Thepanelchairwasagastroenterologist.
Conflicts of interest of all participants were managed according to 
ANMSpolicies.Atthetimeofappointment,amajorityoftheguide-
linepanel,includingthechairandthevice-chair,hadnoconflictsof
interest as defined and judged byANMS policies.Thismanuscript
was prepared by committee members and a patient advocate who 
served as part of the committee in order to incorporate patient val-
uesandpreferenceswhiledevelopingrecommendations,asperthe
GRADEmethodology.6 A librarian conducted the literature search
and two GRADE experts reviewed and graded the literature. The
reader is referred to the accompanying technical review for a more 
detailed understanding of the process and additional details about 
individualstudies.Thecommitteehadfour in-personmeetingsand
multiple conference calls during this process. Committee members 
except for the twoGRADE expertsvoted on all recommendations
and either “agreed” or “disagreed” and votes were tallied.
Recommendations for the diagnosis of CVS, suggested investi-
gations,treatmentprotocolfortheemergencydepartment(ED),and
algorithm for management are also provided. These recommendations 
are based on best practices and consensus of the committee members. 
These were formulated based on review of the available literature and 
thecollectiveexperienceofthecommitteememberswhohavetaken
care of more than 3000 patients with CVS in their practices.
With increasing attention paid to use of cannabis in CVS,
Cannabinoid Hyperemesis Syndrome (CHS) has been proposed as a 
distinctentitybytheRomeFoundation.7-10CHS,theroleofcanna-
bisinhyperemesis,andtheoverlapbetweenCHSandCVSarede-
scribed in a separate manuscript included with these CVS guidelines.
2  | TRE ATMENT OF CYCLIC VOMITING 
SYNDROME
TreatmentofCVSshouldbebasedonabiopsychosocialcaremodel,
integrating lifestyle modification, prophylactic and/or abortive
medications, and evidenced-based psychotherapy to address psy-
chiatric comorbidity.Ongoing care by a dedicated teamwill likely
improve overall healthcare outcomes. Given the lack of validated
outcomes to assess the severity of CVS, the committee arbitrar-
ilydefinedseverityasmild,moderate,orseverebasedonthefre-
quencyanddurationofepisodes,needforhealthcareutilization,and




abortive medications and rationale for their use are discussed below 
and are summarized in Table 1.
Key Points
• TheseEvidence-BasedGuidelineson theManagement
of CVS in Adults are based on the GRADE (Grading
of ecommendations, Assessment, Development and
Evaluation) framework and recommendations for the
prophylaxisofCVS,treatmentofacuteattacks,diagno-
sis and overall management of CVS are made.
• The committee strongly recommends that adults with 
moderate-to-severe CVS receive a tricyclic antide-
pressant (TCA) such as amitriptyline, as a first-line
prophylactic medication. For acute attacks, the com-
mittee conditionally recommends using serotonin an-
tagonistssuchasondansetron,and/ortriptanssuchas
sumatriptan or newer agents such as aprepitant (NK1
receptor antagonist) to abort symptoms.
• An individualized treatmentplan for treatmentofCVS
in the emergency department can facilitate care and an 
exampleisprovided.
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3  | PROPHYL AC TIC MEDIC ATIONS IN C VS
3.1 | Recommendation 1. We strongly recommend 
that adults with moderate‐to‐severe CVS receive 
tricyclic antidepressants (TCAs), especially 
amitriptyline, as a first‐line prophylactic medication
Grade: Strong recommendation, very low‐quality evidence. Vote: 100% 
agreement
Amitriptyline (AT) is a tricyclic antidepressant, a mixed sero-
toninandnorepinephrinereuptakeinhibitorthatalsointeractswith





Prophylactic therapywith TCAs should be considered in patients
whohavemoderate-to-severeCVS.Moderate-to-severeCVSisde-
finedbyoneormoreof thefollowing:≥4episodes/year,episodes
>2 days in duration, severe episodes that require emergency de-
partment(ED)visitsorhospitalization,orepisodesthatsignificantly




trials (RCTs) in children.3,15-17 There were fourteen studies that in-
cluded 600 adult and pediatric patients.3,15-27Acrossthesestudies,
413/600 (70%) of patients reported complete or partial improve-




tion in thenumberofCVSepisodes from17 to3, in theduration
ofaCVSepisodefrom6to2days,andinthenumberofEDvisits/
hospitalizationsfrom15to3.3withAT.Kumaretal3 in a retrospec-
tivestudyof70patientsshowedthatthemajorityofpatients(86%)
respondedtotreatmentwithAT.Someofthesepatientswerealso
treated with other agents such as topiramate and mitochondrial sup-
plements suchasCo-Q10andL-carnitine.Anobservational study
found that of 24patientswho receivedAT for at least 3months,
93%hadareductioninsymptomsmeasuredbyavisualanalogscale,
while26%hadcompleteremissionofsymptoms.18
F I G U R E  1  Algorithmfortreatmentofcyclicvomitingsyndrome.AdaptedfromBhandarietal.56
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Themeaneffectivedoseinadultsis75-100mgdailyor1-1.5mg/
kgbodyweight.3,15,28Amitriptyline isbest titrated in10-25mg in-
crements as this improves tolerability by allowing adaptation to and 
preventingdiscontinuationfromsideeffects,particularlydaytimese-
dation. This improves the ultimate efficacy of the medication. Most 
of thepanelistsused10mgbutsomeused25mg.Asalways, this
needs to be individualized based upon the patient response. The in-
cidenceofsideeffectswithATvariesfrom9%to25%althoughthis








and after the target dose is reached. More frequent monitoring will 
varybetweenindividualpatients,basedontheirresponsetoATand
concomitant use of other medications that can prolong the QT inter-
val.ItisrecommendedthattheQTcbemaintainedat<470msecfor
womenand<450msecformen.ThedosageofATshouldbereduced
or stopped if there is QTc prolongation or development of signifi-





higher doses typically used to treat the former.29
The evidence was considered very low quality despite the fact 
that therewere 14 studies, given issueswith selection bias, con-
founding,co-interventions(supplements),andvariationinoutcomes
reportedacross thedifferent studies.Despite this, thecommittee
members including the patient representative unanimously agreed 
thatTCAsareextremelyeffectiveprophylaxisinCVSbasedontheir








3.2 | Recommendation 2. We conditionally 
recommend that adults with moderate‐to‐
severe CVS receive topiramate as an alternate 
prophylactic medication
Grade: Conditional recommendation, very low‐quality evidence. Vote: 
100% agreement
Topiramate may be used as an alternative prophylactic medi-
cationinmoderate-to-severeCVS.Severalstudiesshowthattopi-
ramate is effective in preventingmigraine headaches, but there
is limited evidence on its utility in CVS. One retrospective study 
of 16 children treatedwith topiramate found that 81% became
episodefree,13%showedat least≥50%reduction innumberof
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episodes,andonly6%didnotrespond.30 In a retrospective study 
of18adultstreatedwithprophylactictopiramate,72%had≥50%
reduction in frequency/severity of CVS episodes. Some patients 
on topiramatewerealso receivingATandmitochondrial supple-
ments in this study.3





ache,fatigue,dizziness,ormoodproblems)occur.2,31-33 Weight loss 
fromappetitereductionisasideeffectandmaybedesired, inpa-
tients who are overweight or obese.34-36 We recommend monitor-
ing serum electrolytes and renal function twice a year as metabolic 
acidosis may occur.37,38 Oral bicarbonate supplementation may be 
initiatedifserumbicarbonateis<20mmol/L.Thereisaslightlyin-
creased risk of developing renal stones.39 Female patients should
be informed that topiramate can interfere with the efficacy of oral 
contraceptives.
3.3 | Recommendation 3. We conditionally 
recommend that adults with moderate‐to‐
severe CVS receive aprepitant as an alternate 
prophylactic medication
Grade: Conditional recommendation, very low‐quality evidence. Vote: 
100% agreement
Aprepitant is a relatively new (approved 2003) substance P/
neurokinin1 receptor (NK1)highly selective, high-affinity antago-
nist antiemetic agent.40 It binds to receptors in the nucleus tractus 
solitariusthatmediatetheemeticmotorreflex.Ithasbeenusedto
prevent acute and delayed (>24 hours) vomiting induced by moder-
ateandhighlyemetogenicchemotherapyaswellas inpost-opera-
tivenauseaandvomiting (PONV).Although theplasmahalf-life is
9-13 hours, clinical effectsmay persist for 3-5 days.41 Significant 
inhibitors(eg,grapefruitjuice,clarithromycin)andinducers(eg,en-
zalutamide, topiramate) ofCYP3A4 system increase anddecrease
levels, respectively, andare tobeavoided ifpossible.42 Caution is 
recommended in patients with severe liver disease.
Thereisasingleopen-labeltrialofaprepitantusedprophylacti-












trial of 126 adults with gastroparesis (and related syndromes),
although oral aprepitant (125 mg) failed to significantly reduce nau-
seawhenmeasured by visual analog criteria, it achieved the sec-
ondary outcomes of significant reduction in nausea and vomiting 
severity indexasmeasuredbytheGastroparesisClinicalSymptom
Index.44Most trials in CINV used aprepitant in combinationwith
5HT3 antagonists and corticosteroids.
45,46Ninetaskforcemembers
have used aprepitant prophylactically in adolescents or adults with 
some success in preventing episodes.
Based upon the data in children and adolescents and the clinical 
experinceofcommitteemembers,werecommendinitiatingaprep-
itantasanalternate/second-lineprophylactictreatmentinpatients




sidered when prescribing this medication.
3.4 | Recommendation 4. We conditionally 
recommend that adults with moderate‐to‐severe CVS 
receive zonisamide or levetiracetam as an alternate 
prophylactic medication
Grade: Conditional recommendation, very low‐quality evidence. Vote: 
100% agreement
Zonisamide isanoral sulfonamideanti-epileptic (AED)withdi-
rect influence on sodium and calcium channel function as well as 









The evidence supporting the use of zonisamide or levetiracetam 
as prophylactic therapy in CVS is based on one retrospective case 
series of 20 adult patients.50However, thebenefits of this thera-
peuticapproachhavebeensubstantiatedbyadditionalclinicalexpe-
rience.Intheirreport,Clouseandcolleaguesdescribedadultswho
suffered from about 12 episodes/year and had failed to respond to 
TCA therapy. The substantial reduction in the number ofCVS at-
tacksfromameanof1.3±0.3to0.5±0.2episodes/yearinresponse




(minimum: 3months). Side effects of fatigue, confusion, impaired
concentration, or headachewere commonly reportedby patients,
but those with more severe side effects tolerated the switch to the 
alternativeAEDverywell.
The doses of zonisamide and levetiracetam used for CVS pro-
phylaxismirror those used to prevent seizures. For zonisamide, a
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startingdoseof100mgPOdailyistypical,withweeklyincreasesof
100mg/daytotargetafinaldoseof400mg/day.Levetiracetamis
typically started at 500 mg PO in divided doses twice daily and in-
creasedby500mgweeklyuntilthetargetdoseof~1000–2000mg/
dayisachieved.Genericformulationsarenotparticularlyexpensive.
Neither agent requires routine serummonitoring of liver or renal
function,butlowerdosesshouldbeusedinthosewithestablished
liverorrenaldisease.Finally,newerAEDsrelatedtozonisamideand
levetiracetam, such as lacosamideor brivaracetam, are nowavail-
able,butitremainstobeseeniftheseneweragentsareaseffective
inprophylaxisofCVSepisodes.
3.5 | Recommendation 5. We conditionally 
recommend using mitochondrial supplements such as 
Co‐Q10, and riboflavin as prophylactic therapy in the 
treatment of CVS. Mitochondrial supplements may be 
used concurrently with other prophylactic agents
GRADE: Conditional recommendation, very low‐quality evidence. Vote: 
100% agreement
Mitochondrial dysfunction is a probable contributory fac-
tor in the pathogenesis of both CVS and migraine headache.51,52 
Migrainesufferersexhibitdecreasedrespiratorycomplexfunction
inimagingandenzymeassaysandislikelypresentinCVS,though
specific studies are lacking.53 In addition, both conditions have
strong preferential maternal inheritance.3,54,55 Childhood CVS fre-
quently progresses to migraine headache. There is a high preva-
lence of migraine among close relatives with CVS and both often 















and preparations used (gel capsules, liquids, tablets). Boles et al19 
recommendedCo-Qdoseof10mg/kgperdayintwodivideddoses,
up to200mgbid (either in liquidor gel capsule formulation). For
refractory cases, they suggest obtainingbloodCo-Q10 levels and
increasingthedosetoachieveatargetbloodlevelof3mg/L.
Riboflavin,aprecursorof flavinmononucleotideandflavin-ad-




adherence,andexcellenttolerability.58 In a systematic review of the 
efficacyofriboflavinasprophylactictherapy,riboflavinwasassoci-
ated with a positive therapeutic effect in five clinical trials in adults 
with migraine.59 Most migraine studies report doses of riboflavin of 
200mgtwicedaily.Baseduponthisindirectevidence,onemayalso
consider riboflavin as an additional prophylactic supplement in adult 
CVS patients.
4  | ABORTIVE MEDIC ATIONS IN C VS
4.1 | Recommendation 6. We conditionally 
recommend using triptans like sumatriptan to abort 
symptoms of a CVS episode
Grade: Conditional recommendation, moderate‐quality evidence. Vote: 
>80% agreement
Sumatriptan is a serotonin agonist approved for the treatment 
of migraine.60Itlikelybindstothe5-HT1Band5-HT1D receptor sub-
classes in themeninges,producingconstrictionofdistendeddural
blood vessels. The efficacy of sumatriptan in migraine is due to mul-
tiplesitesofaction(vascular,neural,andcentral).Therearereports
ofefficacyofsumatriptan inabdominalmigraine,aconditionclas-
sified in the subgroup of childhood periodic syndromes.61,62 CVS is 
also in the subgroup of periodic syndromes that include migraine 
and its equivalents. While the mechanisms causing CVS are not well 
defined,thereisaclear-cutclinical,familial,therapeutic,andlikely
pathogenic parallel with migraine headaches.63
In one non–placebo-controlled study of 11 children with CVS,
the efficacy of sumatriptan treatment was high in those with a fam-
ily history of migraine compared to cases without a family history of 
migraine.64However, thosewithoutafamilyhistoryofmigrainestill
responded to sumatriptan in50%of their attacks. In this study, su-
matriptan was administered by SC injection in nine and via nasal route 
inthreepatients.Althoughthenumberofpatientswassmall,thead-
ministrationof sumatriptan reducedvomiting inninepatients (82%)
and the nasal route seemed less effective. Three other case reports 
describe the efficacy of injectable sumatriptan in aborting episodes 
of CVS.65 The committee believes that sumatriptan is effective in the 
acutetreatmentofCVSalthoughrandomizedplacebo-controlledstud-
iesinvestigatingtheefficacyofsumatriptaninCVSattacksarelacking.
We recommend administration of triptans during the prodrome 
orwithin30-45minutesoftheonsetofvomitinginanepisode.The
efficacy appears to diminish after the first 60 minutes. We recom-
mend nasal and injectable administration given uncertain oral ab-
sorptioninCVS.Forthenasalroute,werecommendadministering
thedrug,whiletheheadisgentlyflexedforwardtoavoidnasopha-
ryngeal dripping of the drug which can have a bitter taste.66 We rec-
ommendusingsumatriptanasanasalsprayat20mginitially,while
a comparable subcutaneous sumatriptan dose in adults is 6 mg. The 
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tothosewithunderlyingcoronaryarterydisease,peripheralvascular
disease,hypertension,orstrokedueitsvasoconstrictorproperties.
4.2 | Recommendation 7. We conditionally 
recommend using serotonin antagonists such as 
ondansetron to abort symptoms of a CVS episode
Vote: 100% agreement
Ondansetronisaselective5-hydroxytryptaminetype3(5-HT3) 
receptor antagonist.67 It acts by blocking afferent 5-HT3 recep-
tors on the vagus peripherally and centrally in the chemoreceptor 
trigger zone (CTZ) of the area postrema within the medulla oblon-
gata. These actions result in decreased circulating serotonin at the 
CTZ level, reducing symptomsofnauseaandvomiting inaffected
patients.67,68Ondansetron ismetabolized in the liver byCYP3A4,
CYP1A2,andCYP2D6andisexcretedrenally.69
Despite itswideuse inCVS, there is a lackof clinical trials of
5-HT3antagonistsinthiscondition.However,thereareampledata
demonstratingtheefficacyoftheseagents inCINVandpostoper-
ative nausea and vomiting (PONV) in treating acute, delayed, and
anticipatory nausea and vomiting.70,71 Studies indicate that ondan-




ing5-HT3 receptor antagonists with other abortive agents such as 
anxiolyticsandphenothiazinesforsedationmaybemoreeffective
in aborting an episode than monotherapy. We note that there is a 
wide variability of responses with a few patients having a complete 
abortive responsewhile themajority experience attenuationbut
notcessationoftheepisode.Adverseeffectsareuncommonand
may include headache, dizziness, drowsiness, diarrhea, constipa-
tion,andinfrequentlyextrapyramidalreactions.73AbaselineEKG
tocheck forQTcprolongation is recommended inadultsprior to
initiatingthismedication.Werecommendusing8mgofondanse-
tron as a sublingual preparation or rectally (reformulated) at the 
onset of the prodrome in combination with other abortive medica-
tionsliketriptans,andanxiolyticstoabortanepisodeofCVS.The
oral route should be avoided as patients are usually unable to toler-
ate oral preparations during an episode and also due to the unpre-
dictable absorption of medications during an episode of vomiting.
4.3 | Recommendation 8. We conditionally 
recommend aprepitant to abort symptoms of a 
CVS episode
Grade: Conditional recommendation, very low‐quality evidence. Vote: 
>80% agreement
There is a single open-label trial of oral aprepitant used as
abortive treatment of CVS in children and adolescents who were 
refractory to conventional treatment.43 All children >20 kgwere
given the standard regimen used in chemotherapy-induced nau-
seaandvomiting (CINV)of125mg initiallyduringtheprodrome,
then80mgdailyforthefollowing2daysasneeded.Oralaprep-
itant could be retained if administered during a prodrome at least 
30minutesbeforetheonsetofvomiting.Attheendof12months,
this recurring abortive regimen significantly reduced the duration 
ofepisodesfrom5daysto1day,thenumberofvomitsfrom9to
4timesperhour,andthenumberofhospitaladmissionsfrom9to
2.5.Sideeffects appear tobemild, and themedicationwaswell
tolerated. There are no data on the use of intravenous fosaprepi-
tant(phosphorylatedprodrugofaprepitant)inCVS,althoughithas
beenusedeffectivelyinmoderateandhighlyemetogenicCINV.74





the prodrome and before the onset of vomiting. The target individu-
als in whom abortive aprepitant is recommended include those who 
are refractory to standard abortive therapy (eg, sumatriptan and
ondansetron) and those who have a defined prodrome or a predict-
able periodicity (episode which occurs in relation to the menstrual 
cycle) in which aprepitant can be initiated a day or two before the 
anticipated onset of vomiting. Difficulties with obtaining insurance 
approval for aprepitant and IV fosaprepitant have been a barrier to 
its use despite demonstrated efficacy.
5  | TRE ATMENT OF COMORBID 
CONDITIONS
5.1 | Recommendation 9. We suggest screening 
and treatment for comorbid conditions such as 
anxiety, depression, migraine headache, autonomic 
dysfunction, sleep disorders, and substance use. We 
suggest referral to appropriate allied health services 
(psychologist, psychiatrist, neurologist, sleep, or 
substance use specialist) as indicated
Vote: 100% agreement
Psychiatricconditions, includinganxiety,panic,anddepression,
are common in adults with CVS,18,75 with one systematic review 
findingaprevalenceof39.7%(CI:33.6-46.1).76However,fewstud-
ies used standardized diagnostic interviews to ascertain psychiatric 
disorders,withmostreportingthepresenceofpsychiatricconditions
based on either a patient report/chart review or via a screening in-
strument.Onecasereportdescribedpersistentnauseathatprovoked
anxiety,leadingtoconditionedanticipatorynauseaandvomitingthat
inturnaggravatedthepatient'sCVS.77 Other studies reported that 
panic symptoms can trigger episodes of CVS.75,78Taranukhaetal79 
recentlyreportedthat41%ofadultswithCVShadhighdegreesof
psychological distress measured by the Basic Symptom Inventory. 
Anxiety andmood symptomsmaybothbe risk factors for precip-
itating episodes of CVS or as a consequence of CVS. It is prudent 
toassessforpsychiatriccomorbidityinadultCVSpatients.Further,
severalpopulation studieshave found increasedsymptomburden,
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functionaldisability,decreasedqualityoflife,andincreasedhealth-
carecostswhenmedicalandmentalhealthconditionsco-occur.80
Migraine headache (including a family history of migraine) is 
closely linkedwithCVS.4,5 The prevalence of migraine headaches in 
adultswithCVSvariesbetween13%and70%.15 75Furthermore,57%
of adult CVS patients (with or without migraine) were reported to 
haveafirstand/orsecond-degreerelativewithmigrainesormigraine







of the disorders have been abolished.
Autonomic function in CVS has been extensively investigated,
with findings thatmanyCVSpatientsexhibit autonomicdysregula-
tion.Inastudyof20adultpatientswithCVS,7(35%)hadpostural
tachycardia.81Another study in 22 adultswithCVS found 5 (23%)
witheitherposturaltachycardiaororthostatichypotension,while10
(47%)ofthe21pediatricCVSpatientsstudiedbyChelimskyetal82,83 
reportedorthostatic intolerance.Abnormalities in skin sympathetic
responses and thermoregulatory sweat tests have also been reported. 
ThereportbyChelimskyetal84 in children suggests that treatment of 
the underlying autonomic dysfunction reduces the number of vomit-
ingepisodes;however,thetreatmentofCVSandposturalorthostatic
tachycardia syndrome (POTS) overlaps in the use of supplemental 
fluid intake,conditioning,andpropranolol.Concurrenttreatmentof
the underlying autonomic disorder may be needed particularly in the 
setting of severe orthostatic symptoms such as chronic daily nausea 
and subacute symptoms in between acute vomiting episodes.
Widespreaddrugusagehasbeenfound inCVSwith39%-81%
usingcannabis,19%alcohol,36%tobacco,and17%reliantonnar-
cotics for pain management.85,86 Although none of these studies
containedaspecificcomparisongroup,mostofthesefiguresappear
tobehigherthanthosefoundinthegeneralpopulation.Co-occur-
ring substance use or abuse can interact with medications for the 
managementofCVSandcomplicatetreatment,andthus,standard
screening for such disorders and appropriate treatment is indicated. 
The role of cannabis in CVS and CHS is discussed in detail in a sepa-
rate paper in this supplement.
5.2 | Recommendation 10. We suggest that 
techniques such as meditation, relaxation and 
biofeedback be offered as complementary therapy 
in CVS. These measures are generally devoid of side 
effects and may improve overall well‐being and 
patient care outcomes
Vote: 100% agreement
Cyclic vomiting syndrome is a functional GI disorder that is 
thought to be due to altered brain-gut interaction.87-89 Episodes
of CVS are often triggered by stressors. Functional neuroimaging
studies have shown distinct differences in functional connectivity in 
regionsofthebrainsuchastheinsularcortexthatareassociatedwith
processingofemotion,nausea,andpain.Thissupportsthehypothe-
sis that symptoms are centrally mediated and highlights the potential 




dehydration may help reduce both migraine headache and the fre-
quencyofCVSepisodes. Theemphasis on self-management skills
may also contribute to the patient developing an enhanced sense of 
efficacy. There is scant literature addressing the use of complemen-
tarytechniquesinadultCVS.Relaxationandbiofeedbackcombined
with cognitive behavioral therapy were successful in reducing the 
frequency of CVS episodes in one adolescent case study.90
The recommendations provided are summarized in Table 1 and 
aredrawnfromasystematicGRADEevaluationoftheliterature(1-6
and8) and expert committee consensus (7,9 and10).Weprovide
theserecommendationswithanappreciationofthelimited,andlow-
quality evidence provided from the literature aiming to bridge the 
gapbetweenwhatweknowandhowwecanbesthelppatientsat
the present time.
5.3 | Consensus statement on diagnosis and 
management of CVS
The following section addresses the diagnosis, appropriate inves-
tigations, and an algorithm for the treatment of CVS. These rec-
ommendations are formulated based on expert opinion, available
literature, and indirect evidence and as such are not amenable to
GRADEmethodology.Theyareintendedtoprovideasuccinct,com-
prehensive overview of the diagnosis and management of CVS.
5.4 | Diagnosis
Cyclic vomiting syndrome has typical clinical features, and the
hallmarkofCVSisthepresenceofintermittentepisodesofsevere
nausea and vomiting interspersed with symptom-free intervals.
However,patientsmayexperienceinter-episodicnauseaordyspep-
sia and may not be completely asymptomatic in between typical epi-
sodes. This feature of adult CVS was recognized for the first time in 
theupdatedRomeIVcriteriaforCVS(Table2).Atthepresenttime,
theexpertcommitteeendorsestheRomeIVdiagnosticcriteriafor
CVSbut also acknowledges that the sensitivity and specificity of
these criteria have not been subjected to rigorous study. The use 
of chronic cannabis in CVS has led to a putative new diagnosis of 
CHS and is discussed in a separate article in this special supplement.
TherearefourphasesofCVS:prodromalphase,vomitingphase,
recovery,andasymptomaticorinter-episodicphase.75 During the pro-
drome,patientshaveintensenausea,somewithsymptomsofpanic.
Autonomic symptoms such as diarrhea, cold and hot flashes, and
profuse sweating may also be present. This is followed by the acute 
emetic phase where patients will have severe vomiting and retching. 
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Thevomitingcanoftenberelentlessvaryingfrom1to6times/hour,
and the retching often persists even after the stomach has been com-
pletelyemptied.Abdominalpainisverycommonandcanbepresent








hours though this is variable. The four phases of CVS are depicted 
inFigure2.Therecoveryphasevaries fromhours todays,andpa-
tientsareslowlyabletoresumeoralintakeandreturntobaseline.A
proposed data collection sheet for use in clinic to capture the salient 
features while entertaining a diagnosis of CVS is shown in Table 3.




nausea becomes superimposed on acute vomiting episodes resulting 
incontinuoussymptomatologyanddisability.Encounteringapatient
in a coalescent phase of their illness presents a diagnostic challenge as 
the illness may not be recognizable as CVS by most clinicians. When 
thetypicalepisodicpatternislost(oftenoccurringoveryears),acare-
ful history focusing on symptoms at the onset of the disorder is im-
portant tomake an accuratediagnosis, asmost patients endorse a
discernable cyclic pattern that was part of the initial presentation.
5.5 | Investigations










is limited published data pertaining to approach.
Abasicworkupforapatientwithpreviouslyuninvestigatedep-
isodes of vomiting should include biochemical, endoscopic, and
potentially radiographic assessments. Biochemical testing should 






















Both opiates and cannabis can delay gastric emptying.92Lastly,pa-
tients with any localizing neurological symptoms should undergo 
brain imaging (CT or MRI) and would justify referral to a neurologist.
Investigations for hypothyroidism (thyroid-stimulating hor-
moneand/orT4/T3serumlevels),acutepancreatitis(serumlipase),
Addisondisease(serumcortisoland/oranadrenocorticotropinstim-
ulation (ACTH)stimulation test),mitochondrialdisease (serum lac-
tate,pyruvate),or lesscommonmetabolicdisorderssuchasacute
intermittentporphyria(urineporphyrins)maybeconsidered,espe-
cially with supporting symptoms.
OnceadiagnosisofCVShasbeenestablished,werecommend
assessing severity of CVS, identifying triggers, and recognizing
comorbid conditions.An algorithm for themanagement ofCVS is
showninFigure1.Asalways,treatmentoptionsshouldbediscussed
with the patient and patient preferences should be considered. 
F I G U R E  2   Schematic representation of the four phases of cyclic 
vomiting syndrome and their therapeutic goals.75 
TA B L E  2   Rome IV criteria for cyclic vomiting syndrome





toms can be present between cycles 
Supportiveremarks:
 Personal or family history of migraine headaches
Criteria must be fulfilled for the last 6 months with symptom onset 
at least 3 months before diagnosis
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Ongoing care with a team to provide support is crucial to achieve 
good outcomes.
5.6 | Treatment of CVS in the 
emergency department
The present review evaluates the evidence for effectiveness of dif-
ferent drugs used in the acute care setting. The review demonstrates 
the paucity of Grade I evidence for the effectiveness of any one 
drug. It is possible that some of these drugs are more effective when 
used sequentially or in combination.2,75,78 The literature is largely si-
lentontheeffectivenessofsequentialdrugregimens,combinations





it isvery likely that the response to individualmedicationswillbe
heterogenousalthoughpossiblethatsingledrugswillworkbestfor
awell-definedsubgroup.Itislikelythatacombinationofdrugswill
TA B L E  3   Proposed data collection sheet for cyclic vomiting syndrome
1 Demographics Age,Gender,Race














3 CVS episode Prodromalphase—presence,duration,symptomsa
4 Prior prophylactic treatment (dose and dura-





5 Prior abortive medications Triptans(suchassumatriptan),serotoninreceptorantagonists(ondansetron),
benzodiazepines,NK1receptorantagonists
6 Health care utilization No.ofemergencydepartment/urgentcarevisits/hospitalizationsoverthepast
year and since onset of CVS symptoms











9 Social history Smokingnicotine,bcannabis,alcoholuse
10 Investigations Bloodwork,EGD,Imagingstudiesoftheabdomen
aAbortivemedicationssuchastriptansandondansetronandanxiolyticsaremosteffectivewhenusedearlyintheprodromalphase.
bData collection sheet for cannabis use is given in a separate manuscript on cannabis use in CVS in this supplement. 
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continue to be the preferred approach for the treatment of most of 
thesepatients.Forthisbroadgroup,acombinationofanti-emetics,
analgesics,andsedationare likelytobeeffectiveforsymptomatic
relief of rescue therapy.96,97 Discussions with neurologists in the 
drafting of this review indicated that the improper administration 
of nasal triptans may account for their seeming ineffectiveness.66A
“head forward” technique vastly improves drug delivery to anteriorly 
placednasal receptors.As in asthma,patienteducation shouldbe
includedaspartofthetreatmentapproach.Forpatientswhereanxi-
etyisaprominentfeature,amedicationprotocolthatusesanxiolytic
and sedative drugs may be more effective. There is very limited data 
on the use of benzodiazepines in cyclic vomiting syndrome. That said 
theycanveryhelpfulintheshorttermtoreduceanxietyandsomatic
symptoms in the setting of a vomiting episode in the emergency de-
partment or an acute care setting. The dilemma is that these medica-




were among the 10 most frequently cited drugs in overdose deaths. 
98Thus, foranyconditionwhereanxietyplaysapivotalrole,afo-
cused evaluation should be conducted and the medication treatment 
ofchoice,antidepressants,beconsideredalongwithcognitivebe-
havioraltreatmentofanyunderlyinganxietydisorder.
While opiates may occasionally be required for control of severe 
pain,itispreferabletooptfortheuseofintravenousketorolacand
non-opiatesedationtoavoiddevelopmentofdependenceorpatient




Cyclic vomiting syndrome is a condition that challenges both patients 
and healthcare providers alike due to the considerable morbidity
andmisery associatedwith it and the lack of a clear understand-
ing of pathophysiology and robust therapeutic evidence required 
to advance treatment. The 10 recommendations, the consensus
statement,andtreatmentalgorithmsprovidedaimtobridgethegap
betweenourcurrentknowledgeofCVSandhowwecanbesthelp
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TA B L E  4  Cyclicvomitingsyndromeemergencydepartment(ED)
protocola




companied by profound nausea and/or severe abdominal pain




• Patients are not customarily dehydrated until late in the episode
Therapeutic goal









d Diagnostic imaging at discretion of attending physician
Treatment
1. Intravenous fluids 






b Consider diphenhydramine 50 mg IV and metoclopramide 
10 mg IV










b Opioids may be considered as part of an ongoing treatment 
plan in refractory patientsb
Reassess
1. Treatment failure—intensify treatment as indicated above or 
admit patient
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